ID   A2780
AC   CVCL_0134
SY   A-2780; 2780; A2780S; A2780par
DR   BTO; BTO:0002549
DR   CLO; CLO_0001571
DR   EFO; EFO_0006362
DR   MCCL; MCC:0000027
DR   CLDB; cl193
DR   CLDB; cl194
DR   CLDB; cl4894
DR   AddexBio; C0017002/20
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BCRJ; 0031
DR   BioGRID_ORCS_Cell_line; 329
DR   BioSample; SAMN03472806
DR   BioSample; SAMN10988216
DR   cancercelllines; CVCL_0134
DR   CancerTools; 152706
DR   Cell_Model_Passport; SIDM00210
DR   ChEMBL-Cells; CHEMBL3308421
DR   ChEMBL-Targets; CHEMBL614004
DR   Cosmic; 688090
DR   Cosmic; 755844
DR   Cosmic; 849607
DR   Cosmic; 906804
DR   Cosmic; 923108
DR   Cosmic; 948284
DR   Cosmic; 987394
DR   Cosmic; 1093558
DR   Cosmic; 1102819
DR   Cosmic; 1139223
DR   Cosmic; 1198265
DR   Cosmic; 1305309
DR   Cosmic; 1609529
DR   Cosmic; 1707564
DR   Cosmic; 1708387
DR   Cosmic; 1709251
DR   Cosmic; 1945872
DR   Cosmic; 1995331
DR   Cosmic; 2582805
DR   Cosmic; 2674698
DR   Cosmic-CLP; 906804
DR   DepMap; ACH-000657
DR   ECACC; 93112519
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 906804
DR   GEO; GSM184388
DR   GEO; GSM184389
DR   GEO; GSM383925
DR   GEO; GSM503257
DR   GEO; GSM659370
DR   GEO; GSM711722
DR   GEO; GSM827312
DR   GEO; GSM851909
DR   GEO; GSM886853
DR   GEO; GSM887918
DR   GEO; GSM1001419
DR   GEO; GSM1001420
DR   GEO; GSM1001488
DR   GEO; GSM1291126
DR   GEO; GSM1291129
DR   GEO; GSM1340577
DR   GEO; GSM1374380
DR   GEO; GSM1374381
DR   GEO; GSM1669581
DR   GEO; GSM2474971
DR   GEO; GSM4845007
DR   GEO; GSM4845008
DR   IARC_TP53; 21161
DR   ICLC; HTL98008
DR   LiGeA; CCLE_809
DR   LINCS_LDP; LCL-1518
DR   Lonza; 207
DR   MetaboLights; MTBLS156
DR   MetaboLights; MTBLS1014
DR   NCI-DTP; A2780
DR   PharmacoDB; A2780_40_2019
DR   PRIDE; PXD001176
DR   PRIDE; PXD003105
DR   PRIDE; PXD003252
DR   PRIDE; PXD003668
DR   PRIDE; PXD013811
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0134
DR   PubChem_Cell_line; CVCL_0134
DR   Wikidata; Q54606559
DR   Ximbio; 152706
RX   PubMed=1348364;
RX   PubMed=1999494;
RX   PubMed=2429947;
RX   PubMed=2751261;
RX   PubMed=3335022;
RX   PubMed=3539322;
RX   PubMed=3986765;
RX   PubMed=6372095;
RX   PubMed=6954533;
RX   PubMed=7927910;
RX   PubMed=8012063;
RX   PubMed=8557231;
RX   PubMed=9041185;
RX   PubMed=11103784;
RX   PubMed=11416159;
RX   PubMed=12080474;
RX   PubMed=15677628;
RX   PubMed=18273836;
RX   PubMed=19714814;
RX   PubMed=20164919;
RX   PubMed=20204287;
RX   PubMed=20215515;
RX   PubMed=22328975;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=22705003;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25846456;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27235858;
RX   PubMed=27397505;
RX   PubMed=27561551;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=28546799;
RX   PubMed=30485824;
RX   PubMed=30894224;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=33287223;
RX   PubMed=35839778;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=A2780
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/2/cell-lines-detail-64.html
WW   https://tcpaportal.org/mclp/
WW   https://www.phe-culturecollections.org.uk/media/113526/a2780-cell-line-profile.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: African American.
CC   Doubling time: 25.3 +- 1 hours (PubMed=3539322); 16 hours (PubMed=25984343); 18.41 hours (GrayJW panel).
CC   HLA typing: A*26:03,26:03; B*37:04,49:01; C*02:02,07:01; DQB1*06:07,06:07; DRB1*01:01,01:01 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-low) (PubMed=15677628; Sanger).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (PubMed=25846456).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (PubMed=25230021).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: Metabolome analysis.
CC   Omics: N-glycan profiling by lectin array.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Genome ancestry: African=93.08%; Native American=0%; East Asian, North=2.76%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=4.17% (PubMed=30894373).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): AddexBio; Cosmic-CLP; ECACC; ICLC; PubMed=11416159; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12,13
ST   D16S539: 11,12,13 (ICLC)
ST   D16S539: 11,13 (AddexBio; Cosmic-CLP; ECACC; PubMed=25230021; PubMed=25877200; PubMed=30485824)
ST   D18S51: 16,18
ST   D19S433: 12
ST   D21S11: 28 (PubMed=25230021; PubMed=25877200)
ST   D21S11: 28,29 (PubMed=30485824)
ST   D2S1338: 21,22
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 15,17
ST   FGA: 19,24
ST   Penta D: 8,9
ST   Penta E: 10,13
ST   TH01: 6
ST   TPOX: 8,10
ST   vWA: 15,16
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070;
RA   Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C.,
RA   Anderson M.E.;
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=1999494; DOI=10.1172/JCI115080;
RA   Parker R.J., Eastman A., Bostick-Bruton F., Reed E.;
RT   "Acquired cisplatin resistance in human ovarian cancer cells is
RT   associated with enhanced repair of cisplatin-DNA lesions and reduced
RT   drug accumulation.";
RL   J. Clin. Invest. 87:772-777(1991).
//
RX   PubMed=2429947; DOI=10.20772/cancersci1985.77.9_941;
RA   Tsuruo T., Hamilton T.C., Louie K.G., Behrens B.C., Young R.C.,
RA   Ozols R.F.;
RT   "Collateral susceptibility of adriamycin-, melphalan- and
RT   cisplatin-resistant human ovarian tumor cells to bleomycin.";
RL   Jpn. J. Cancer Res. 77:941-945(1986).
//
RX   PubMed=2751261;
RA   Mazzoni A., Trave F., Canti G., Franco P.;
RT   "Effect of the tiapamil analog RO11-2933 on cellular sensitivity to
RT   antitumor drugs in sensitive and multidrug resistant human ovarian
RT   cancer cells.";
RL   Anticancer Res. 9:367-371(1989).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3539322;
RA   Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R.,
RA   Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C.,
RA   Ozols R.F.;
RT   "Characterization of a cis-diamminedichloroplatinum(II)-resistant
RT   human ovarian cancer cell line and its use in evaluation of platinum
RT   analogues.";
RL   Cancer Res. 47:414-418(1987).
//
RX   PubMed=3986765;
RA   Louie K.G., Behrens B.C., Kinsella T.J., Hamilton T.C.,
RA   Grotzinger K.R., McKoy W.M., Winker M.A., Ozols R.F.;
RT   "Radiation survival parameters of antineoplastic drug-sensitive and
RT   -resistant human ovarian cancer cell lines and their modification by
RT   buthionine sulfoximine.";
RL   Cancer Res. 45:2110-2115(1985).
//
RX   PubMed=6372095; DOI=10.1126/science.6372095;
RA   Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W. Jr., Ozols R.F.;
RT   "Reversal of adriamycin resistance by verapamil in human ovarian
RT   cancer.";
RL   Science 224:994-996(1984).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=7927910; DOI=10.1002/ijc.2910590118;
RA   Huxham I.M., Barlow A.L., Lewis A.D., Plumb J., Mairs R.J., Gaze M.N.,
RA   Workman P.;
RT   "Differential intracellular processing of the anthracycline drug
RT   ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human
RT   ovarian cancer cells as studied with confocal laser scanning
RT   microscopy and image analysis.";
RL   Int. J. Cancer 59:94-102(1994).
//
RX   PubMed=8012063;
RA   Cimoli G., Valenti M., Parodi S., Mazzoni A., De Sessa F., Conte P.,
RA   Russo P.;
RT   "Reversal of 'atypical'-multidrug resistance by recombinant human
RT   tumor necrosis factor in the human ovarian cancer cell line
RT   A2780-DX3.";
RL   Oncol. Res. 5:311-323(1993).
//
RX   PubMed=8557231; DOI=10.1006/gyno.1996.0014;
RA   Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.;
RT   "p53 gene mutation analysis and antisense-mediated growth inhibition
RT   of human ovarian carcinoma cell lines.";
RL   Gynecol. Oncol. 60:72-80(1996).
//
RX   PubMed=9041185;
RA   Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.;
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//
RX   PubMed=11103784;
RA   Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D.,
RA   Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J.;
RT   "Large-scale serial analysis of gene expression reveals genes
RT   differentially expressed in ovarian cancer.";
RL   Cancer Res. 60:6281-6287(2000).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I.,
RA   Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.,
RA   Auersperg N., Birrer M.J.;
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=18273836; DOI=10.1002/gcc.20547;
RA   Prasad M., Bernardini M., Tsalenko A., Marrano P., Paderova J.,
RA   Lee C.-H., Ben-Dor A., Barrett M.T., Squire J.A.;
RT   "High definition cytogenetics and oligonucleotide aCGH analyses of
RT   cisplatin-resistant ovarian cancer cells.";
RL   Genes Chromosomes Cancer 47:427-436(2008).
//
RX   PubMed=19714814; DOI=10.1021/pr800856b;
RA   Cicchillitti L., Di Michele M., Urbani A., Ferlini C., Donati M.B.,
RA   Scambia G., Rotilio D.;
RT   "Comparative proteomic analysis of paclitaxel sensitive A2780
RT   epithelial ovarian cancer cell line and its resistant counterpart
RT   A2780TC1 by 2D-DIGE: the role of ERp57.";
RL   J. Proteome Res. 8:1902-1912(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=28546799; DOI=10.1186/s12014-017-9155-z;
RA   Zhao R., Qin W.-J., Qin R.-H., Han J., Li C., Wang Y.-S., Xu C.-J.;
RT   "Lectin array and glycogene expression analyses of ovarian cancer cell
RT   line A2780 and its cisplatin-resistant derivate cell line A2780-cp.";
RL   Clin. Proteomics 14:20.1-20.10(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894224; DOI=10.1186/s40659-019-0220-0;
RA   Viscarra T., Buchegger K., Jofre I.A., Riquelme I., Zanella L.,
RA   Abanto Marin M., Parker A.C., Piccolo S.R., Roa J.C., Ili C.G.,
RA   Brebi P.;
RT   "Functional and transcriptomic characterization of
RT   carboplatin-resistant A2780 ovarian cancer cell line.";
RL   Biol. Res. 52:13.1-13.13(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=33287223; DOI=10.3390/ijms21239218;
RA   Szenajch J., Szabelska-Beresewicz A., Swiercz A., Zyprych-Walczak J.,
RA   Siatkowski I., Goralski M., Synowiec A., Handschuh L.;
RT   "Transcriptome remodeling in gradual development of inverse resistance
RT   between paclitaxel and cisplatin in ovarian cancer cells.";
RL   Int. J. Mol. Sci. 21:9218.1-9218.30(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//